ANN ARBOR STAGE IVA HODGKIN LYMPHOMA
Clinical trials for ANN ARBOR STAGE IVA HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new ANN ARBOR STAGE IVA HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for ANN ARBOR STAGE IVA HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Targeted drug joins fight against childhood lymphoma
Disease control OngoingThis large, late-stage trial is testing if adding a targeted drug called brentuximab vedotin to standard chemotherapy works better than chemotherapy alone for children and young adults with newly diagnosed, high-risk Hodgkin lymphoma. The study aims to see if the new combination …
Matched conditions: ANN ARBOR STAGE IVA HODGKIN LYMPHOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New drug combo offers hope for older hodgkin lymphoma patients unsuitable for standard chemo
Disease control OngoingThis study is testing a combination of two immunotherapy drugs, nivolumab and brentuximab vedotin, for older adults or those who cannot tolerate standard chemotherapy for untreated Hodgkin lymphoma. The goal is to see how well this drug combination controls the cancer by helping …
Matched conditions: ANN ARBOR STAGE IVA HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Academic and Community Cancer Research United • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC